findmyKOL
Clinical trialNCT05061251WithdrawnEarly phase 1Interventional

Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma

SponsorUniversity of Texas Southwestern Medical CenterEnrollment0GliomaIDH Mutation
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study aims to look at how BAY 2402234 responds in body in patients with recurrent glioma.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BAY 2402234
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Dec 2021
Primary completion
1 Dec 2022
Completion
1 Dec 2023
Last update posted
11 Jan 2022
Registered enrollment
0
Registry id
NCT05061251
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.